AlphaQuest LLC Acquires 48,250 Shares of Avanos Medical, Inc. $AVNS

AlphaQuest LLC raised its holdings in Avanos Medical, Inc. (NYSE:AVNS) by 130.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 85,341 shares of the company’s stock after purchasing an additional 48,250 shares during the quarter. AlphaQuest LLC’s holdings in Avanos Medical were worth $987,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Avanos Medical by 49.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock valued at $31,000 after purchasing an additional 894 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after purchasing an additional 5,083 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Avanos Medical in the second quarter valued at $126,000. Finally, Inscription Capital LLC bought a new position in shares of Avanos Medical in the third quarter valued at about $135,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Kerr Holbrook sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the sale, the senior vice president directly owned 83,860 shares in the company, valued at approximately $922,460. This represents a 15.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.64% of the stock is owned by corporate insiders.

Avanos Medical Price Performance

Shares of Avanos Medical stock opened at $13.45 on Tuesday. The company has a 50-day simple moving average of $11.92 and a two-hundred day simple moving average of $11.67. Avanos Medical, Inc. has a twelve month low of $9.30 and a twelve month high of $17.54. The stock has a market capitalization of $624.40 million, a price-to-earnings ratio of -1.32 and a beta of 1.09. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.12 by $0.10. The company had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period last year, the firm earned $0.33 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Analysts forecast that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wall Street Zen raised shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Zacks Research raised Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Avanos Medical has a consensus rating of “Reduce”.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.